Global Type 1 Diabetes

Type 1 Diabetes Comprehensive Study by Application (Hospitals, Diagnostic clinics), End Users (Adults, Hospitals and Clinics, Homecare Providers), Product (Insulin, Blood Glucose Monitoring Devices, Other Devices and Accessories, Diabetes Management Software and Apps), Insulin Analog (Rapid acting insulin analogs, Long acting insulin analogs, Premix insulin analogs) Players and Region - Global Market Outlook to 2030

Type 1 Diabetes Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Type 1 diabetes is also previously known by juvenile diabetes or diabetes mellitus. It is a multifactorial chronic and autoimmune condition throughout which the body produces a minute or no insulin in the pancreas. Insulin hormone is required by the body to get glucose from the bloodstream into the cells to yield energy. Most of the diabetes cases can be categorized as type 1a autoimmune disease, where the destruction of pancreatic beta cells is observed, low production of insulin disrupts blood glucose homeostasis as well as minor cases of type 1b idiopathic diabetes mellitus. This kind of diabetes is rare and develops during adolescence or childhood, but can also be observed in adults. Frequent urination, increased hunger, excessive thirst, weight loss, and fatigue are some of the common symptoms. Diabetes diagnostic devices encompass lancets, test strips, analog blood meter along with insulin delivery devices such as insulin pump, insulin syringe, insulin pen, and insulin jet injectors.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledEli Lilly and Company (United States), Astrazeneca Plc. (United Kingdom), B.Braun Melsungen AG (Germany), Novo Nordisk A/S (Denmark), Sanofi-Aventis US, LLC. (United States), DiaVacs, Inc. (United States), XOMA Corp. (United States), Biodel, Inc. (United States), Macrogenics, Inc. (United States) and Bayer Pharmaceuticals (Germany)


This growth is primarily driven by Rising Awareness among People, Technological Advancement in Insulin Delivery Devices, Rising Number of Chronic Diseases Associated With Diabetes and Increasing Government Initiatives for Diabetes Control.

Globally, a noticeable market trend is evident Increasing Demand for Artificial Pancreas The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Eli Lilly and Company (United States), Astrazeneca Plc. (United Kingdom), B.Braun Melsungen AG (Germany), Novo Nordisk A/S (Denmark), Sanofi-Aventis US, LLC. (United States), DiaVacs, Inc. (United States), XOMA Corp. (United States), Biodel, Inc. (United States), Macrogenics, Inc. (United States) and Bayer Pharmaceuticals (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market is highly fragmented with the presence of various players in the market. Some of the key strategies followed by the players operating in the global lithium foil market were innovation, product development, acquisition, and expansion.

Key Developments in the Market:
In August 2023, Roche partners with Apple to integrate its Accu-Chek Guide blood glucose monitoring system with the Apple Health app, enhancing data sharing and management.
In October 2023, Abbott introduces its FreeStyle Libre 3 system, featuring a sensor with a 14-day wear time and improved accuracy, simplifying glucose monitoring.

Influencing Trend:
Increasing Demand for Artificial Pancreas and Home Infusion Therapy for Diabetes Treatment

Market Growth Drivers:
Rising Awareness among People, Technological Advancement in Insulin Delivery Devices, Rising Number of Chronic Diseases Associated With Diabetes and Increasing Government Initiatives for Diabetes Control

Challenges:
Side Effects Associated With Diabetes Therapies

Restraints:
High Cost of Diagnosis and Treatment and Unfavorable Reimbursement Policies

Opportunities:
Strong Pipeline and Development of Molecules from Newer Class of Diabetes Drugs and Development of Non-Invasive Diabetes Diagnostics And Drug Delivery Devices

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Type 1 Diabetes Market
- Analysis about New Entrants in Type 1 Diabetes Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Type 1 Diabetes Study Sheds Light on
— The Type 1 Diabetes Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Type 1 Diabetes industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Type 1 Diabetes industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Diagnostic clinics
By End Users
  • Adults
  • Hospitals and Clinics
  • Homecare Providers

By Product
  • Insulin
  • Blood Glucose Monitoring Devices
  • Other Devices and Accessories
  • Diabetes Management Software and Apps

By Insulin Analog
  • Rapid acting insulin analogs
  • Long acting insulin analogs
  • Premix insulin analogs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness among People
      • 3.2.2. Technological Advancement in Insulin Delivery Devices
      • 3.2.3. Rising Number of Chronic Diseases Associated With Diabetes
      • 3.2.4. Increasing Government Initiatives for Diabetes Control
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated With Diabetes Therapies
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand for Artificial Pancreas
      • 3.4.2. Home Infusion Therapy for Diabetes Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Type 1 Diabetes, by Application, End Users, Product, Insulin Analog and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Type 1 Diabetes (Value)
      • 5.2.1. Global Type 1 Diabetes by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Diagnostic clinics
      • 5.2.2. Global Type 1 Diabetes by: End Users (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Hospitals and Clinics
        • 5.2.2.3. Homecare Providers
      • 5.2.3. Global Type 1 Diabetes by: Product (Value)
        • 5.2.3.1. Insulin
        • 5.2.3.2. Blood Glucose Monitoring Devices
        • 5.2.3.3. Other Devices and Accessories
        • 5.2.3.4. Diabetes Management Software and Apps
      • 5.2.4. Global Type 1 Diabetes by: Insulin Analog (Value)
        • 5.2.4.1. Rapid acting insulin analogs
        • 5.2.4.2. Long acting insulin analogs
        • 5.2.4.3. Premix insulin analogs
      • 5.2.5. Global Type 1 Diabetes Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Type 1 Diabetes: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astrazeneca Plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. B.Braun Melsungen AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk A/S (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi-Aventis US, LLC. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DiaVacs, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. XOMA Corp. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biodel, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Macrogenics, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer Pharmaceuticals (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Type 1 Diabetes Sale, by Application, End Users, Product, Insulin Analog and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Type 1 Diabetes (Value)
      • 7.2.1. Global Type 1 Diabetes by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Diagnostic clinics
      • 7.2.2. Global Type 1 Diabetes by: End Users (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Hospitals and Clinics
        • 7.2.2.3. Homecare Providers
      • 7.2.3. Global Type 1 Diabetes by: Product (Value)
        • 7.2.3.1. Insulin
        • 7.2.3.2. Blood Glucose Monitoring Devices
        • 7.2.3.3. Other Devices and Accessories
        • 7.2.3.4. Diabetes Management Software and Apps
      • 7.2.4. Global Type 1 Diabetes by: Insulin Analog (Value)
        • 7.2.4.1. Rapid acting insulin analogs
        • 7.2.4.2. Long acting insulin analogs
        • 7.2.4.3. Premix insulin analogs
      • 7.2.5. Global Type 1 Diabetes Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Type 1 Diabetes: by Application(USD Million)
  • Table 2. Type 1 Diabetes Hospitals , by Region USD Million (2018-2023)
  • Table 3. Type 1 Diabetes Diagnostic clinics , by Region USD Million (2018-2023)
  • Table 4. Type 1 Diabetes: by End Users(USD Million)
  • Table 5. Type 1 Diabetes Adults , by Region USD Million (2018-2023)
  • Table 6. Type 1 Diabetes Hospitals and Clinics , by Region USD Million (2018-2023)
  • Table 7. Type 1 Diabetes Homecare Providers , by Region USD Million (2018-2023)
  • Table 8. Type 1 Diabetes: by Product(USD Million)
  • Table 9. Type 1 Diabetes Insulin , by Region USD Million (2018-2023)
  • Table 10. Type 1 Diabetes Blood Glucose Monitoring Devices , by Region USD Million (2018-2023)
  • Table 11. Type 1 Diabetes Other Devices and Accessories , by Region USD Million (2018-2023)
  • Table 12. Type 1 Diabetes Diabetes Management Software and Apps , by Region USD Million (2018-2023)
  • Table 13. Type 1 Diabetes: by Insulin Analog(USD Million)
  • Table 14. Type 1 Diabetes Rapid acting insulin analogs , by Region USD Million (2018-2023)
  • Table 15. Type 1 Diabetes Long acting insulin analogs , by Region USD Million (2018-2023)
  • Table 16. Type 1 Diabetes Premix insulin analogs , by Region USD Million (2018-2023)
  • Table 17. South America Type 1 Diabetes, by Country USD Million (2018-2023)
  • Table 18. South America Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 19. South America Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 20. South America Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 21. South America Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 22. Brazil Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 23. Brazil Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 24. Brazil Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 25. Brazil Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 26. Argentina Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 27. Argentina Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 28. Argentina Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 29. Argentina Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 30. Rest of South America Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 32. Rest of South America Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 33. Rest of South America Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 34. Asia Pacific Type 1 Diabetes, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 37. Asia Pacific Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 38. Asia Pacific Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 39. China Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 40. China Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 41. China Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 42. China Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 43. Japan Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 44. Japan Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 45. Japan Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 46. Japan Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 47. India Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 48. India Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 49. India Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 50. India Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 51. South Korea Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 52. South Korea Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 53. South Korea Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 54. South Korea Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 55. Taiwan Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 56. Taiwan Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 57. Taiwan Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 58. Taiwan Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 59. Australia Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 60. Australia Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 61. Australia Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 62. Australia Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 67. Europe Type 1 Diabetes, by Country USD Million (2018-2023)
  • Table 68. Europe Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 69. Europe Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 70. Europe Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 71. Europe Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 72. Germany Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 73. Germany Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 74. Germany Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 75. Germany Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 76. France Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 77. France Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 78. France Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 79. France Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 80. Italy Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 81. Italy Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 82. Italy Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 83. Italy Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 84. United Kingdom Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 86. United Kingdom Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 87. United Kingdom Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 88. Netherlands Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 89. Netherlands Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 90. Netherlands Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 91. Netherlands Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 92. Rest of Europe Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 94. Rest of Europe Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 95. Rest of Europe Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 96. MEA Type 1 Diabetes, by Country USD Million (2018-2023)
  • Table 97. MEA Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 98. MEA Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 99. MEA Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 100. MEA Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 101. Middle East Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 102. Middle East Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 103. Middle East Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 104. Middle East Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 105. Africa Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 106. Africa Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 107. Africa Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 108. Africa Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 109. North America Type 1 Diabetes, by Country USD Million (2018-2023)
  • Table 110. North America Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 111. North America Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 112. North America Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 113. North America Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 114. United States Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 115. United States Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 116. United States Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 117. United States Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 118. Canada Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 119. Canada Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 120. Canada Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 121. Canada Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 122. Mexico Type 1 Diabetes, by Application USD Million (2018-2023)
  • Table 123. Mexico Type 1 Diabetes, by End Users USD Million (2018-2023)
  • Table 124. Mexico Type 1 Diabetes, by Product USD Million (2018-2023)
  • Table 125. Mexico Type 1 Diabetes, by Insulin Analog USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Type 1 Diabetes: by Application(USD Million)
  • Table 137. Type 1 Diabetes Hospitals , by Region USD Million (2025-2030)
  • Table 138. Type 1 Diabetes Diagnostic clinics , by Region USD Million (2025-2030)
  • Table 139. Type 1 Diabetes: by End Users(USD Million)
  • Table 140. Type 1 Diabetes Adults , by Region USD Million (2025-2030)
  • Table 141. Type 1 Diabetes Hospitals and Clinics , by Region USD Million (2025-2030)
  • Table 142. Type 1 Diabetes Homecare Providers , by Region USD Million (2025-2030)
  • Table 143. Type 1 Diabetes: by Product(USD Million)
  • Table 144. Type 1 Diabetes Insulin , by Region USD Million (2025-2030)
  • Table 145. Type 1 Diabetes Blood Glucose Monitoring Devices , by Region USD Million (2025-2030)
  • Table 146. Type 1 Diabetes Other Devices and Accessories , by Region USD Million (2025-2030)
  • Table 147. Type 1 Diabetes Diabetes Management Software and Apps , by Region USD Million (2025-2030)
  • Table 148. Type 1 Diabetes: by Insulin Analog(USD Million)
  • Table 149. Type 1 Diabetes Rapid acting insulin analogs , by Region USD Million (2025-2030)
  • Table 150. Type 1 Diabetes Long acting insulin analogs , by Region USD Million (2025-2030)
  • Table 151. Type 1 Diabetes Premix insulin analogs , by Region USD Million (2025-2030)
  • Table 152. South America Type 1 Diabetes, by Country USD Million (2025-2030)
  • Table 153. South America Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 154. South America Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 155. South America Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 156. South America Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 157. Brazil Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 158. Brazil Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 159. Brazil Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 160. Brazil Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 161. Argentina Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 162. Argentina Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 163. Argentina Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 164. Argentina Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 165. Rest of South America Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 166. Rest of South America Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 167. Rest of South America Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 168. Rest of South America Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 169. Asia Pacific Type 1 Diabetes, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 171. Asia Pacific Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 172. Asia Pacific Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 173. Asia Pacific Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 174. China Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 175. China Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 176. China Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 177. China Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 178. Japan Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 179. Japan Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 180. Japan Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 181. Japan Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 182. India Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 183. India Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 184. India Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 185. India Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 186. South Korea Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 187. South Korea Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 188. South Korea Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 189. South Korea Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 190. Taiwan Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 191. Taiwan Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 192. Taiwan Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 193. Taiwan Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 194. Australia Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 195. Australia Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 196. Australia Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 197. Australia Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 202. Europe Type 1 Diabetes, by Country USD Million (2025-2030)
  • Table 203. Europe Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 204. Europe Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 205. Europe Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 206. Europe Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 207. Germany Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 208. Germany Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 209. Germany Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 210. Germany Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 211. France Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 212. France Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 213. France Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 214. France Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 215. Italy Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 216. Italy Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 217. Italy Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 218. Italy Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 219. United Kingdom Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 220. United Kingdom Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 221. United Kingdom Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 222. United Kingdom Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 223. Netherlands Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 224. Netherlands Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 225. Netherlands Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 226. Netherlands Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 227. Rest of Europe Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 228. Rest of Europe Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 229. Rest of Europe Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 230. Rest of Europe Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 231. MEA Type 1 Diabetes, by Country USD Million (2025-2030)
  • Table 232. MEA Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 233. MEA Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 234. MEA Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 235. MEA Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 236. Middle East Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 237. Middle East Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 238. Middle East Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 239. Middle East Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 240. Africa Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 241. Africa Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 242. Africa Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 243. Africa Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 244. North America Type 1 Diabetes, by Country USD Million (2025-2030)
  • Table 245. North America Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 246. North America Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 247. North America Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 248. North America Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 249. United States Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 250. United States Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 251. United States Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 252. United States Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 253. Canada Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 254. Canada Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 255. Canada Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 256. Canada Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 257. Mexico Type 1 Diabetes, by Application USD Million (2025-2030)
  • Table 258. Mexico Type 1 Diabetes, by End Users USD Million (2025-2030)
  • Table 259. Mexico Type 1 Diabetes, by Product USD Million (2025-2030)
  • Table 260. Mexico Type 1 Diabetes, by Insulin Analog USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Type 1 Diabetes: by Application USD Million (2018-2023)
  • Figure 5. Global Type 1 Diabetes: by End Users USD Million (2018-2023)
  • Figure 6. Global Type 1 Diabetes: by Product USD Million (2018-2023)
  • Figure 7. Global Type 1 Diabetes: by Insulin Analog USD Million (2018-2023)
  • Figure 8. South America Type 1 Diabetes Share (%), by Country
  • Figure 9. Asia Pacific Type 1 Diabetes Share (%), by Country
  • Figure 10. Europe Type 1 Diabetes Share (%), by Country
  • Figure 11. MEA Type 1 Diabetes Share (%), by Country
  • Figure 12. North America Type 1 Diabetes Share (%), by Country
  • Figure 13. Global Type 1 Diabetes share by Players 2023 (%)
  • Figure 14. Global Type 1 Diabetes share by Players (Top 3) 2023(%)
  • Figure 15. Global Type 1 Diabetes share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 19. Astrazeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Astrazeneca Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 21. B.Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. B.Braun Melsungen AG (Germany) Revenue: by Geography 2023
  • Figure 23. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 24. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 25. Sanofi-Aventis US, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi-Aventis US, LLC. (United States) Revenue: by Geography 2023
  • Figure 27. DiaVacs, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. DiaVacs, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. XOMA Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 30. XOMA Corp. (United States) Revenue: by Geography 2023
  • Figure 31. Biodel, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Biodel, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Macrogenics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Macrogenics, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Bayer Pharmaceuticals (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer Pharmaceuticals (Germany) Revenue: by Geography 2023
  • Figure 37. Global Type 1 Diabetes: by Application USD Million (2025-2030)
  • Figure 38. Global Type 1 Diabetes: by End Users USD Million (2025-2030)
  • Figure 39. Global Type 1 Diabetes: by Product USD Million (2025-2030)
  • Figure 40. Global Type 1 Diabetes: by Insulin Analog USD Million (2025-2030)
  • Figure 41. South America Type 1 Diabetes Share (%), by Country
  • Figure 42. Asia Pacific Type 1 Diabetes Share (%), by Country
  • Figure 43. Europe Type 1 Diabetes Share (%), by Country
  • Figure 44. MEA Type 1 Diabetes Share (%), by Country
  • Figure 45. North America Type 1 Diabetes Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli Lilly and Company (United States)
  • Astrazeneca Plc. (United Kingdom)
  • B.Braun Melsungen AG (Germany)
  • Novo Nordisk A/S (Denmark)
  • Sanofi-Aventis US, LLC. (United States)
  • DiaVacs, Inc. (United States)
  • XOMA Corp. (United States)
  • Biodel, Inc. (United States)
  • Macrogenics, Inc. (United States)
  • Bayer Pharmaceuticals (Germany)
Additional players considered in the study are as follows:
Takeda Pharmaceutical. (Japan) , F. Hoffmann-La Roche Ltd (Switzerland) , Pfizer Inc. (United States) , Sanofi (France) , Eli Lilly (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 241 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Type 1 Diabetes Quantitative research analysis
Global Type 1 Diabetes Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Type 1 Diabetes market are Eli Lilly and Company (United States), Astrazeneca Plc. (United Kingdom), B.Braun Melsungen AG (Germany), Novo Nordisk A/S (Denmark), Sanofi-Aventis US, LLC. (United States), DiaVacs, Inc. (United States), XOMA Corp. (United States), Biodel, Inc. (United States), Macrogenics, Inc. (United States) and Bayer Pharmaceuticals (Germany), to name a few.
North America is dominating the Type 1 Diabetes Market.
"Side Effects Associated With Diabetes Therapies" is seen as one of the major challenges by many Industry Players of Type 1 Diabetes Market
The Type 1 Diabetes market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Type 1 Diabetes market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Type 1 Diabetes Report?

Have a Query? Click Here

Other Related Reports

Food Allergy Comprehensive Study by Type (Corn Allergy, Egg Allergy, Fish Allergy, Meat Allergy, Milk Allergy, Peanut Allergy, Shellfish Allergy, Soy Allergy, Tree Nut Allergy, Wheat Allergy, Others)...
$ 3750
Chemical Peel Comprehensive Study by Type (Light Chemical Peel, Medium Chemical Peel, Deep Chemical Peel), Application (Dermatology Clinics, Hospitals, Others), Chemicals (Alpha-hydroxy Acids (AHAs),...
$ 3450
Xerophthalmia Treatment Comprehensive Study by Type (Cyclosporin, Oral Corticosteroids, Artificial Tears, Punctal Plugs, Omega Supplement), Application (Hospital Pharmacies, Eye Health Clinics), Age ...
$ 3750
Tularaemia Treatment Comprehensive Study by Application (Hospital, Clinic, Others), Disease Type (Ulceroglandular, Glandular, Oculoglandular, Oropharyngeal, Intestinal, Pneumonic, Typhoidal), Drugs T...
$ 3450
Antiarrhythmic Drugs Comprehensive Study by Type (Oral Antiarrhythmic, Intravenous Antiarryhthmic), Application (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), Distribution Channel (Direct...
$ 3350
Oligonucleotide Synthesis Comprehensive Study by Type (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Others), Application (Therapeutic, Research, Diagnostic), End-User (Hospita...
$ 3800